These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 33300850)

  • 21. PML in DMF-treated patients with normal lymphocytes: Worried well or well to be worried?
    Carruthers RL; Healy BC
    Mult Scler; 2016 Mar; 22(3):394-5. PubMed ID: 26163066
    [No Abstract]   [Full Text] [Related]  

  • 22. Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate.
    Bartsch T; Rempe T; Wrede A; Leypoldt F; Brück W; Adams O; Rohr A; Jansen O; Wüthrich C; Deuschl G; Koralnik IJ
    Ann Neurol; 2015 Oct; 78(4):501-14. PubMed ID: 26150206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
    Lehmann-Horn K; Penkert H; Grein P; Leppmeier U; Teuber-Hanselmann S; Hemmer B; Berthele A
    Neurology; 2016 Jul; 87(4):440-1. PubMed ID: 27343070
    [No Abstract]   [Full Text] [Related]  

  • 24. Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.
    Kowalec K; Kingwell E; Carruthers R; Marrie RA; Bernatsky S; Traboulsee A; Ross CJD; Carleton B; Tremlett H
    BMJ Open; 2017 Jun; 7(5):e016276. PubMed ID: 28576902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of dimethyl fumarate (Tecfidera™) on lymphocyte counts: A potential contributor to progressive multifocal leukoencephalopathy risk.
    Khatri BO; Garland J; Berger J; Kramer J; Sershon L; Olapo T; Sesing J; Dukic M; Rehn E
    Mult Scler Relat Disord; 2015 Jul; 4(4):377-9. PubMed ID: 26195059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
    Sainz de la Maza S; Sabin Muñoz J; Pilo de la Fuente B; Thuissard I; Andreu-Vázquez C; Galán Sánchez-Seco V; Salgado-Cámara P; Costa-Frossard L; Monreal E; Ayuso-Peralta L; García-Vasco L; García-Domínguez JM; Martínez-Ginés ML; Muñoz Fernández C; Díaz-Díaz J; Oreja-Guevara C; Gómez-Moreno M; Martín H; Rubio-Flores L; Blasco MR; Villar-Guimerans LM; Aladro Y;
    Mult Scler Relat Disord; 2022 Mar; 59():103669. PubMed ID: 35150979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
    Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
    Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.
    Longbrake EE; Cantoni C; Chahin S; Cignarella F; Cross AH; Piccio L
    Mult Scler; 2018 May; 24(6):728-738. PubMed ID: 28480794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation.
    Caldito NG; O'Leary S; Stuve O
    Mult Scler; 2021 Jul; 27(8):1306-1308. PubMed ID: 33620273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions.
    Vola EA; Petracca M; Cocozza S; De Angelis M; Carotenuto A; Pontillo G; Morra VB; Tedeschi E; Lanzillo R
    BMC Neurol; 2021 Apr; 21(1):146. PubMed ID: 33820529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
    Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
    CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dimethyl fumarate associated lymphopenia in clinical practice.
    Longbrake EE; Cross AH
    Mult Scler; 2015 May; 21(6):796-7. PubMed ID: 25432948
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
    Fleischer V; Friedrich M; Rezk A; Bühler U; Witsch E; Uphaus T; Bittner S; Groppa S; Tackenberg B; Bar-Or A; Zipp F; Luessi F
    Mult Scler; 2018 Apr; 24(5):632-641. PubMed ID: 28436295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.
    De Mercanti SF; Gned D; Matta M; Iudicello M; Franchin E; Clerico M
    J Investig Med High Impact Case Rep; 2020; 8():2324709620939802. PubMed ID: 32646245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High CD4+:CD8+ ratios with herpes zoster infections in patients with multiple sclerosis on dimethyl fumarate.
    Balshi A; Saart E; Pandeya S; Dempsey J; Baber U; Sloane JA
    Mult Scler; 2023 Oct; 29(11-12):1465-1470. PubMed ID: 37572049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical commentary for "Progressive multifocal leukoencephalopathy on dimethyl fumarate with preserved lymphocyte count but deep T-cells exhaustion".
    Berger JR
    Mult Scler; 2021 Apr; 27(4):644-645. PubMed ID: 32686584
    [No Abstract]   [Full Text] [Related]  

  • 37. Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
    Zecca C; Antozzi CG; Torri Clerici V; Ferrazzini M; Mantegazza RE; Rossi S; Gobbi C
    Acta Neurol Scand; 2018 Jun; 137(6):623-625. PubMed ID: 29205270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis.
    Tsantes E; Curti E; Ferraro D; Lugaresi A; Baldi E; Montepietra S; Immovilli P; Simone AM; Mancinelli L; Strumia S; Vitetta F; Foschi M; Ferri C; Ferrarini C; Sola P; Granella F
    Eur J Neurol; 2021 Jan; 28(1):269-277. PubMed ID: 32931130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.
    D'Amico E; Zanghì A; Leone C; Tumani H; Patti F
    Drug Saf; 2016 Dec; 39(12):1163-1174. PubMed ID: 27696299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.